Oncology Central

Biomaterial-based local drug delivery to brain tumors


Glioblastoma (GBM) is the most prevalent and aggressive malignant brain tumor with a median survival from diagnosis of 12–15 months. Standard-of-care treatment consists of radical surgery followed by radiotherapy with concomitant systemic temozolomide. Nevertheless, due to the infiltrative nature of GBM, this treatment strategy almost universally fails to eradicate minimal volume residual disease, which typically recurs within 2 cm from the original lesion [1].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.